Materials and methods for nerve grafting, selection of nerve grafts, and in vitro nerve tissue culture

• US 6,972,168 B2
• Filed: 08/13/2002
• Issued: 12/06/2005
• Est. Priority Date: 08/13/2001
• Status: Expired due to Term

• Current Assignee: University of Florida Research Foundation, Incorporated (State University System of Florida)
• Original Assignee: University of Florida Research Foundation, Incorporated (State University System of Florida)
• Inventors: Muir, David F.
• Primary Examiner(s): Afremova, Vera
• Application Number:
  US10/218,864
• Publication Number:
  US 20030040112A1
• Time in Patent Office: 1,211 Days
• Field of Search: 435/1.1, 435/368
• US Class Current: 435/1.1
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 35/30 Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
• CPC Class Codes: A61K 38/51 Lyases (4)
• CPC Class Codes: A61L 2430/32 for nerve reconstruction
• CPC Class Codes: A61L 27/227 Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
• CPC Class Codes: A61L 27/3604 characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
• CPC Class Codes: A61L 27/3675 Nerve tissue, e.g. brain, spinal cord, nerves, dura mater
• CPC Class Codes: A61L 27/3683 subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
• CPC Class Codes: A61L 27/3687 characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
• CPC Class Codes: A61L 27/383 Nerve cells, e.g. dendritic cells, Schwann cells
• CPC Class Codes: A61L 27/3878 Nerve tissue, brain, spinal cord, nerves, dura mater
• CPC Class Codes: A61L 31/047 Other specific proteins or polypeptides not covered by A61L31/044 - A61L31/046
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The subject invention pertains to compositions and methods for culturing nerve tissue in vitro and nerve grafts produced using such methods. The compositions and methods of the subject invention can be employed to restore the continuity of nerve interrupted by disease, traumatic events or surgical procedures. The invention also concerns methods for promoting repair of damaged nerve tissue using the present compositions and nerve tissue treated according to such methods.

Claims

1. A method for promoting repair of a damaged nerve, the method comprising:

culturing a nerve graft in vitro under predegenerating conditions that remodel the nerve graft and that increase the neurite-promoting activity of the nerve graft when subsequently implanted;

rendering the nerve graft acellular by killing cells in the nerve graft; and

implanting the nerve graft at a site of damage.

2. The method according to claim 1, wherein said culturing of the nerve graft in vitro is for a period of time that achieves an increase in axon ingress and extent of growth within the nerve graft when subsequently implanted.

3. The method according to claim 1, wherein the increase in neurite-promoting activity is as determined by an in vitro neurite outgrowth assay of the nerve graft.

4. The method according to claim 3, wherein the in vitro neurite outgrowth assay comprises a cryoculture assay.

5. The method according to claim 1, wherein the increase in neurite-promoting activity is as determined by an in vivo neurite outgrowth assay of the nerve graft.

6. The method according to claim 1, wherein said culturing of the nerve graft in vitro is for a period of time within the range of about 24 hours to about 96 hours.

7. The method according to claim 1, wherein said culturing of the nerve graft in vitro is for a period of time within the range of about 24 hours to about 72 hours.

8. The method according to claim 1, wherein said culturing of the nerve graft in vitro is for a period of time within the range of about 24 hours to about 48 hours.

9. The method according to claim 1, wherein said culturing of the nerve graft in vitro is conducted at a temperature within the range of about 10°

C. to about 37°

C. a period of time of about 48 hours.

10. The method according to claim 1, wherein said culturing of the nerve graft in vitro is conducted at a temperature within the range of about 30°

C. to about 37°

C.

11. The method according to claim 1, wherein said culturing of the nerve graft in vitro is conducted at a temperature of about 37°

C.

12. The method according to claim 1, wherein rendering the nerve graft acellular by killing cells in the nerve graft comprises a process selected from the group consisting of freeze-killing and chemical treatment.

13. The method according to claim 1, wherein said method further comprises freezing the nerve graft for storage.

14. The method according to claim 13, wherein said freezing is carried out after said culturing in vitro.

15. The method according to claim 1, wherein said culture comprises placing the nerve graft in contact with culture medium.

16. The method according to claim 15, wherein the culture medium comprises defined medium.

17. The method according to claim 15, wherein the culture medium comprises defined medium supplemented with serum.

18. The method according to claim 15, wherein the culture medium comprises undefined medium.

19. The method according to claim 1, wherein the nerve graft is mammalian tissue.

20. The method according to claim 1, wherein the nerve graft is mammalian tissue, selected from the group consisting of human tissue, non-human primate tissue, porcine tissue, rodent tissue, and bovine tissue.

21. The method according to claim 1, wherein the nerve graft is human tissue.

22. The method according to claim 1, wherein the nerve graft comprises peripheral nerve tissue.

23. The method according to claim 1, wherein the damaged nerve comprises nerve tissue of the central nervous system.

24. The method according to claim 1, wherein said method further comprises applying a tissue adhesive to the damaged nerve, or to the nerve graft, or to both the damaged nerve and the nerve graft.

25. The method according to claim 1, wherein the nerve graft is a terminal nerve graft.

26. The method according to claim 1, wherein the nerve graft is an interpositional nerve graft.

27. The method according to claim 1, wherein said method further comprises resecting the damaged nerve prior to said implanting of the nerve graft.

28. The method according to claim 1, wherein the nerve graft is autologous with the damaged nerve.

29. The method according to claim 1, wherein the nerve graft is allogeneic with the damaged nerve.

30. The method according to claim 1, wherein the nerve graft is xenogeneic with the damaged nerve.

31. The method according to claim 1, wherein said method further comprises conducting an in vitro neurite outgrowth assay of the nerve graft after said culturing.

32. The method according to claim 31, wherein the in vitro neutrite outgrowth assay comprises a cryoculture assay.

33. The method according to claim 1, wherein said method further comprises conducting an in vivo neurite outgrowth assay of the nerve graft after said culturing.

34. The method according to claim 1, wherein the nerve graft comprises peripheral nerve tissue and wherein said implanting results in axonal growth into basal lamina tubes of the nerve graft accompained by recipient-derived Schwann cells, thereby promoting repair of the damaged nerve.

35. The method according to claim 1, wherein the nerve graft comprises mammalian tissue selected from the group consisting of human tissue, porcine tissue, and bovine tissue.

36. The method according to claim 1, wherein the nerve graft comprises nerve tissue of the central nervous system.

37. The method according to claim 1, wherein the damaged nerve comprises nerve tissue of the peripheral nervous system.

38. A method for promoting repair of a damaged nerve, the method comprising:

culturing a nerve graft in vitro under predegenerating conditions that increase the neurite-promoting activity of the nerve graft when subsequently implanted, the conditions comprising a temperature within the range of about 10°

C. for a period of time within the range of about 24 hours to about 96 hours;

rendering the nerve graft acellular by killing cells in the nerve graft; and

implanting the nerve graft at a site of damage.

39. The method according to claim 38, wherein said nerve graft comprises an allograft or xenograft.

40. The method according to claim 38, wherein said nerve graft comprises human tissue.

41. The method according to claim 38, wherein said nerve graft comprises procine tissue or bovine tissue.

42. The method according to claim 38, wherein said nerve graft comprises nerve tissue of the peripheral nervous system.

43. The method according to claim 38, wherein said nerve graft comprises nerve tissue of the central nervous system.

44. The method according to claim 38, wherein said nerve graft comprises nerve tissue of the peripheral nervous system.

45. The method according to claim 38, wherein said damaged nerve comprises nerve tissue of the central nervous system.

46. A method for promoting repair of a damaged nerve, the method comprising:

placing a nerve graft in conditions in vitro that are permissive to the activation and proliferation of cells within the nerve graft, are permissive to the activity of enzymes produced by cells within the nerve graft, are permissive to the degeneration and remodeling of the nerve graft in vitro, and increase the neurite-promoting activity of the nerve graft when subsequently implanted;

rendering the nerve graft acellular by killing cells in the nerve graft; and

implanting the nerve graft at a site of damage.